All articles by Abi Millar

  1. The problem of manipulated data

    In August, Novartis came under fire for submitting manipulated data in an application to the FDA. The problem lay with…
    Read More…

    2 Dec
  2. A safer ride: the latest innovation in targeted cancer treatment

    Antibody-drug conjugates (ADCs) hold the potential to change the nature of cancer treatment. Unlike classic chemotherapy – in which a…
    Read More…

    28 Nov
  3. Is growth factor protein the future of Parkinson’s treatment?

    In February 2019, the pioneering GDNF clinical trials programme finally published its full results. A major, multimillion-pound project, which ran…
    Read More…

    31 Oct
  4. Proteomics and the promise of ‘enriching’ clinical trials

    Proteomics – the study of the proteome – is widely used within drug discovery. A portmanteau of ‘protein genome’, the…
    Read More…

    29 Oct
  5. Q&A: an eye on innovation with SparingVision

    Retinitis pigmentosa (RP), a genetic disorder of the eyes, is one of the leading causes of blindness. Thought to affect…
    Read More…

    22 Oct
  6. Why is pharma so bad at sharing clinical trial data?

    Over the last few decades, pharma companies have been under ever-mounting pressure to report their clinical trial data. Beginning in…
    Read More…

    21 Oct
  7. From start-ups to the SIX Swiss Exchange – a Swiss success story

    The Swiss life sciences industry is an obvious success story. Boasting a number of heavy-hitters, including Novartis and Roche, along…
    Read More…

    17 Oct
  8. ConcePTION: tackling the unknowns of medication in pregnancy

    The majority of pregnant women take some kind of medication. Whether it’s for a pregnancy-associated ailment or an existing health…
    Read More…

    16 Oct
  9. How do cancer cells communicate and can it help us catch them?

    Earlier this year, Ecole polytechnique fédérale de Lausanne (EPFL) researchers were studying melanoma cancer cells when they made a surprising…
    Read More…

    15 Oct
  10. Understanding drug-resistant TB

    Drug-resistant tuberculosis (DR-TB) is a serious, and growing, public health threat. Despite attracting less media attention than other diseases of…
    Read More…

    14 Oct
Close
Close
Close

Go Top